$60M B round to propel Landos through Phase II IBD trials

Landos' $60 million series B will enable it to complete two Phase II trials, one each in ulcerative colitis and Crohn's disease, of lead product BT-11.

Chairman, President and CEO Josep Bassaganya-Riera told BioCentury he expects the funding to last Landos Biopharma Inc. (Blacksburg,

Read the full 430 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers